Home » Newsletters » BioWorld Science

BioWorld Science

June 6, 2013

View Archived Issues

Janssen presents phase III results from QUEST-2 and PROMISE trials of simeprevir

UMC Utrecht Holding divulges new fusion proteins

Shionogi and TB alliance set to collaborate

Allergan advances novel glaucoma compound into preclinical development

Researchers at Variation Biotechnologies patent new vaccines for HCMV infection

First-in-human evaluation of a DNAzyme in adults with nodular basal cell carcinoma

CSL Behring doses first patient in part 3 of global AFFINITY trial program

Researchers from MD Anderson Cancer Center present novel cancer gene therapy

PhaseBio begins first-in-human phase I study of long-acting basal insulin for diabetes

NIH will fund antibacterial resistance research network at Duke University

The Medicines Company enters agreement to acquire ProFibrix

NB Health Laboratory and Mercachem expand partnership

Prolor Biotech begins pivotal phase III trial of hGH-CTP

First-in-human data for vantictumab, an antibody targeting the Wnt pathway

Tunitas Therapeutics receives phase II SBIR grant to advance asthma program

Phase II Pluristem Therapeutics trial to be put on clinical hold

IL-23 receptor modulator peptide shows potential in animal models of arthritis

BTF as a biomarker of severe events in patients with AF

Bayer acquires majority interest in Conceptus

FDA grants fast track designation to NNZ-2566 in Rett syndrome

Almirall patents novel agents for respiratory disorders

The Vanderbilt University discloses new allosteric modulators of the M1 receptor

Novel XIAP inhibitors presented by Bristol-Myers Squibb and Ensemble Therapeutics

Researchers at Allergan design novel FPRL1 ligands

BioMarin commences phase III program for PKU treatment candidate

FDA approves lenalidomide for relapsed/refractory mantle cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...